Kuros MagnetOs: First Trial Results

Kuros Biosciences announced promising preliminary results from the first of its five planned randomized controlled trials for the MagnetOs product family, comparing MagnetOs Granules to the gold standard of autograft bone.

Data from the prospective, multi-center, intra-patient-controlled trial showed a fusion rate for MagnetOs of 78% vs. 42% for...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us